SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biogen
BIIB 173.93+0.8%1:48 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: William Partmann who wrote (1026)6/13/1999 1:01:00 AM
From: P.M.Freedman  Read Replies (2) of 1686
 
Bill--Another key issue to which you, as a long term investor, should pay attention is one of the key patents of Biogen (U.S. Patent No. 4,530,901 entitled "Recombinant DNA Molecules and Their Use in Producing Interferon-Like Polypeptides," issued on July 23, 1985) will be expired on July 22, 2003. Therefore, Biogen must have another lead drug in the markets by that time. Neither Amevive nor Antova, the two drugs someone claimed coming soon, can play the leading role as Avonex.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News